NCT04413552View on ClinicalTrials.gov

INDV-2000 First in Human

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

July 6, 2020

Primary Completion Date

April 13, 2021

Study Completion Date

April 13, 2021

Conditions
Opioid Dependence
Interventions
DRUG

INDV-2000

INDV-2000 will be administered as either powder in solution or powder in capsule, depending on dose administered.

DRUG

Placebo

Placebo will be administered as either powder in solution or powder in capsule, depending on dose administered.

Trial Locations (1)

66212

Altasciences Clinical Kansas, Overland Park

Sponsors

Lead Sponsor

Indivior Inc.
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Indivior Inc.

INDUSTRY

NCT04413552 - INDV-2000 First in Human | Biotech Hunter | Biotech Hunter